Alpha-Lipoic Acid and Synthetic Analogs for Insulin-Independent GLUT-4 Activation: A Systematic Review

Background: Impaired GLUT-4 translocation and reduced skeletal muscle glucose uptake are central features of insulin resistance and type 2 diabetes mellitus. Alpha-lipoic acid (ALA) has been reported to enhance glucose uptake via insulin-independent activation of AMP-activated protein kinase (AMPK), and synthetic ALA analogs have been proposed to improve its pharmacokinetic and metabolic properties.

Methods: A PRISMA-guided systematic review was performed using PubMed, Scopus, Web of Science, and Google Scholar. Original in vitro, in vivo, human, pharmacokinetic, and computational studies evaluating ALA or ALA-derived analogs in relation to AMPK, GLUT-4, glucose uptake, or bioavailability were included. Data were summarized narratively and in evidence tables.

Results: Of 1,781 records identified, 51 studies met the inclusion criteria. Experimental studies in adipocytes, skeletal muscle, liver, and other tissues consistently showed that ALA activates AMPK and increases GLUT-4 translocation and glucose uptake, even in insulin-resistant models. Pharmacokinetic investigations demonstrated low and variable oral bioavailability, rapid reduction to dihydrolipoic acid, and a short half-life, supporting the rationale for optimized derivatives. Computational and synthetic analog studies indicated that lipophilic, ester- or amide-modified ALA analogs can display improved binding affinity and predicted metabolic stability compared with native ALA.

Conclusions: ALA exerts robust insulin-independent metabolic effects through AMPK activation and GLUT-4 recruitment, but its clinical utility is constrained by pharmacokinetic limitations. Synthetic ALA analogs and bioinformatics-guided design represent promising strategies to enhance ALA’s stability, potency, and translational potential.